ARTICLE | Clinical News
Otelixizumab: Phase III data
March 14, 2011 7:00 AM UTC
Top-line data from the double-blind, international Phase III DEFEND-1 trial in 272 patients ages 12-45 with new-onset Type I diabetes showed that once-daily 3.1 mg IV otelixizumab for 8 days missed th...